Mounjaro/Zepbound 12.5mg/Dose

Mounjaro® / Zepbound™ 12.5mg/Dose – Powerful Support for Weight Loss & Type 2 Diabetes Management

Experience next-level care with Mounjaro® (tirzepatide), also marketed as Zepbound™, at a potent 12.5mg per dose—a trusted treatment option designed for adults seeking effective control of type 2 diabetes and/or medical weight management. This once-weekly injectable medication offers dual-action benefits by targeting GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, mimicking natural hormone activity to help regulate blood sugar and reduce appetite.

Key Benefits:

• Clinically Proven Weight Loss: Zepbound has shown significant results in weight reduction in people with and without diabetes.

• Advanced Glycemic Control: Mounjaro helps lower A1C levels effectively when combined with diet and exercise.

• Once-Weekly Dosing: Simplifies your routine with a convenient, easy-to-use prefilled pen.

• Dual-Incretin Therapy: Works on two hormones, unlike other medications that act on GLP-1 alone.

Product Details:

• Name: Mounjaro® / Zepbound™

• Active Ingredient: Tirzepatide

• Strength: 12.5 mg per dose

• Form: Prefilled injectable pen

• Administration: Subcutaneous injection, once weekly

• Indications:

  • Mounjaro: Type 2 diabetes management

  • Zepbound: Chronic weight management (in adults with obesity or overweight with at least one weight-related condition)

Important Safety Information:

• Not for use in patients with type 1 diabetes.

• Do not use if you or any family member has had medullary thyroid carcinoma (MTC) or MEN 2 syndrome.

• Common side effects may include nausea, vomiting, diarrhea, and decreased appetite.

Talk to your healthcare provider to find out if Mounjaro/Zepbound 12.5mg is right for your health goals.

Mounjaro only

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

2.5 mg SC qWeek x 4 weeks initially; THEN increase to 5 mg SC qWeek

If additional glycemic control needed, increase by 2.5-mg increments after at least 4 weeks at current dose

Maximum dose: 15 mg SC qWeek

Note: 2.5-mg dose is intended for treatment initiation and is not effective for glycemic control

Weight Management

Zepbound only

Indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least 1 weight-related comorbid condition

Initial dose

• Initiate with low dose and gradually escalate to maintenance dose of 2.5 mg/week SC to minimize GI adverse reactions
• Note: 2.5-mg dose is intended for treatment initiation and not for chronic weight management

Maintenance dose

• After 4 weeks, increase to 5 mg SC qWeek
• May increase in 2.5-mg increments, after at least 4 weeks on current dose
• Recommended maintenance dosages are 5 mg, 10 mg, or 15 mg SC qWeek
• Consider treatment response and tolerability when selecting maintenance dosage
• If maintenance dosage not tolerated, consider lower maintenance dosage

Zepbound only

Indicated to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity

10-15 mg SC qWeek

Dosage Modifications

Renal impairment

• Any stage, including end-stage renal disease: No dosage adjustment required

Hepatic impairment

• Any stage: No dosage adjustment required

Dosing Considerations

Limitations of use

• Not studied in patients with history of pancreatitis

• Mounjaro

  • Not indicated for type 1 diabetes mellitus

• Zepbound

  • Do not coadminister with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist
  • Safety and efficacy in combination with other products intended for weight management, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established

Frequently Asked Questions (FAQs)

Mounjaro® / Zepbound™ 12.5mg/Dose

1. What is Mounjaro / Zepbound 12.5mg used for?

Mounjaro® is prescribed to help manage blood sugar levels in adults with type 2 diabetes.
Zepbound™ is approved for chronic weight management in adults with obesity or who are overweight with at least one weight-related condition (e.g., high blood pressure, type 2 diabetes, or high cholesterol).

2. What is the active ingredient in Mounjaro / Zepbound?

The active ingredient is tirzepatide, a dual GIP and GLP-1 receptor agonist that mimics natural hormones to help regulate appetite, insulin response, and blood sugar levels.

3. How do I take Mounjaro / Zepbound 12.5mg?

It is administered as a subcutaneous injection (under the skin) once per week, using a prefilled pen. Your doctor will show you how to use the injection properly.

4. How soon can I expect results?

Some patients may notice weight loss or improved blood sugar levels within the first few weeks, but full benefits typically appear over several months when used consistently with diet and exercise.

5. What are the most common side effects?

Common side effects may include:

• Nausea

• Diarrhea

• Vomiting

• Constipation

• Decreased appetite

• Fatigue

These often lessen over time as your body adjusts.

6. Is Mounjaro / Zepbound the same medication?

Yes, both contain the same drug, tirzepatide. The difference lies in their approved uses:

• Mounjaro: For type 2 diabetes

• Zepbound: For weight loss

7. Can I take this medication if I don’t have diabetes?

Zepbound is approved for people without diabetes but who have obesity or are overweight with a related health condition. Mounjaro is only indicated for people with type 2 diabetes.

8. Can I use Mounjaro / Zepbound with other medications?

You should discuss all medications and supplements with your healthcare provider. Some drugs, especially other diabetes or weight loss medications, may need to be adjusted to avoid side effects like low blood sugar.

9. Are there any serious risks I should be aware of?

Yes. Tirzepatide should not be used if:

• You or a family member has a history of medullary thyroid cancer

• You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

• You are pregnant or breastfeeding (consult your doctor)

10. How do I store the injection pens?

Store in the refrigerator (36°F to 46°F / 2°C to 8°C).
If needed, it can be stored at room temperature (up to 86°F / 30°C) for up to 21 days. Do not freeze.

Vendor: Peptidesciencesusa